Pregnancy risk in Sjögren’s & scleroderma Meta-analysis (n=4,820) shows ↑ risk of miscarriage in Sjögren’s (RR 1.8) & ↑ preterm birth in SSc (RR 2.4). Calls for preconception counseling & multidisciplinary high-risk OB care. @RheumNow #ACR25 Abstract #1398

The axSpA Registry of Ireland (ASRI): 10% reported depression, w/ higher prev in older cohorts. Pts w/ depression had ⬆️peripheral involvement, ⬆️dse activity & poor functional status 💡Consider the impact of non-inflamm factors in dse burden #ACR25 @RheumNow Abs1409 https://t.co/yDfHA24M6e

• https://x.com/RHEUMarampa/status/1982834673966612660/photo/1

Icotrokinra, the new kid on the bloc! Targeted oral peptide IL-23R-inhibitor Effective in Ph2 and Ph3 in PSO Adults Data in Adolescents (12-18yo) with PSO ICO 200mg QD 44pts vs. PBO 22pts 16wks All pts received ICO wk16-wk24 Clear/Almost clear skin IGA 0/1 84% vs. 24% PASI 90 https://t.co/77YvXtdLi1

• https://x.com/AurelieRheumo/status/1982834233430196411/photo/1
• https://x.com/AurelieRheumo/status/1982834233430196411/photo/1
• https://x.com/AurelieRheumo/status/1982834233430196411/photo/1

@RheumNow on Social Media: ✧ virtual learning is the future of medicine ✧use digital strategies to filter good data online- AI can help focus interests & stay up to date - ex. Consensus or Feedly! ✧ peer to peer learning through social media enhances learning #ACR25 https://t.co/n6MzhYoz0n

• https://x.com/doctorkails/status/1982834149141733834/photo/1

NEREA registry study on mortality in progressive pulmonary fibrosis in SARD-ILD. 158 patients. Median survival 7.8 years. DMARD use associated improved mortality. @RheumNow #ACR25 Abstr#1024 https://t.co/rK1caGi2r4

• https://x.com/RichardPAConway/status/1982833416073625649/photo/1

Eat #fibre helps #rheumatoid #arthritis! #RCT #RA w #MTX Adding #super fibre Mean #DAS28 3.8 7TJC, SJC2 Small N +RCT Super fibre group ⬆️ #EULAR response ✅ improve #TH17 &TREG response 🤷‍♀️ tolerability and ease to use dietary super fibre #ACR25 @RheumNow @ACRheum abst#LB15 https://t.co/ME6bsj4Ec7

• https://x.com/Janetbirdope/status/1982833161366024268/photo/1
• https://x.com/Janetbirdope/status/1982833161366024268/photo/1

ADA-biosimilar use surged just before CVS formulary change then dropped sharply after. In RISE data, uptake reached 25% of users overall. Formulary policies reshape prescribing, but sustaining adoption needs alignment with patient access and preferences. @RheumNow #ACR25 A#1042

A post-hoc analysis from the ReFlaP study showed that there was a significant correlation between PsAID12 & HAQ scores MDA-PsAIDrem (SN 82.6% SP97.1%) and MDA-PsAIDlow (SN 90.7% SP 91.2%) Potential alternative for HAQ in MDA criteria? #ACR25 @RheumNow Abs1411 https://t.co/QAxKsuhtDq

• https://x.com/RHEUMarampa/status/1982832157505589530/photo/1
• https://x.com/RHEUMarampa/status/1982832157505589530/photo/1

In high-risk psoriasis patients with nail disease, Secukinumab reduced PsA onset over 5 years with a total exposure of 1022 patient-years. Annual incidence dropped from 2.7 to 0.49 per 100 patient-years. Data from the real world SERENA study. Abstract 1463 @RheumNow #ACR25

In this MTX+PNL vs TCZ+PNL in GCA study, we saw 5 pts on MTX+PNL get PJP, very surprising. @EBRheum asked what I knew/hoped he’d ask: why did this happen? PJP is v rare in GCA (https://t.co/oPN0dpvG8Q) & with MTX in other diseases. Worth interrogation! #ACR25 ABST0891 @RheumNow https://t.co/rsbScryIFR

• https://www.sciencedirect.com/science/article/abs/pii/S0049017222002050
• https://x.com/drdavidliew/status/1982831653023256722/photo/1

POETYK-PsA 1 & 2 Phase 3 RCT TYK2i Deucravacitinib Pooled analysis 640+pts PBO vs. 640+pts DEUCRA 6mg QD MDA 12% vs 22% All elements of MDA response sig different except for Leeds enthesitis index DAPSA Remission 2% vs. 9% PsARC 42% vs. 61% PASDAS -1 vs. -1.7 mCPDAI -1.2 vs. -1.9 https://t.co/OTOFxTOrRp

• https://x.com/AurelieRheumo/status/1982831486026826168/photo/1
• https://x.com/AurelieRheumo/status/1982831486026826168/photo/1

Many GLP-1 drugs in the pipeline for management in #OA #ACR25 @rheumnow https://t.co/y3UCp0CcUb

• https://x.com/bella_mehta/status/1982831363565731941/photo/1

Semaglitide did help in weight loss and decrease in pain in knee OA https://t.co/240sR5An3m #acr25 @rheumnow Question is that is the pain decrease is secondary to weight loss or an independent effect? https://t.co/R2v5YDP3A5

• Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis | NEJM
• https://x.com/bella_mehta/status/1982830500915089558/photo/1
• https://x.com/bella_mehta/status/1982830500915089558/photo/1
• https://x.com/bella_mehta/status/1982830500915089558/photo/1

GLP-1 receptor agonists reduce mortality in PsA Tsibadze et al retrospectively compared ~4k PsA on GLP-1 to ~86k PsA not After propensity matching, those treated with GLP-1: - lower risk MACE - lower risk overall death @RheumNow #ACR25 Abst 0849 https://t.co/EuojrDq0Fj

• https://x.com/Dr_Brian_MD/status/1982830407365341680/photo/1

Is MTX worth anything in GCA? METOGiA: MTX 52w vs TCZ 52w for GCA MTX didn’t achieve non-inferiority to TCZ, but: - clearly it does something - continue both >1y: after MTX/TCZ therapy ended, they ended up with same relapse-free survival, cumulative GC #ACR25 ABST0891 @RheumNow https://t.co/WvvkHKIXuQ

• https://x.com/drdavidliew/status/1982829882553082184/photo/1
• https://x.com/drdavidliew/status/1982829882553082184/photo/1
• https://x.com/drdavidliew/status/1982829882553082184/photo/1